Dr. Weeks’ Comment: Dr. Rudolf Steiner introduced these mistletoe preparations to the world in the 1920’s and since then this form of medicine has been very impressive: in the mistletoe are two different lectins which kill cancer in two different ways.
Iscador Study on Osteosarcoma
We are pleased to inform you that the poster of Alessandra Longhi et al. concerning the Osteosarcoma study with Iscador P was accepted at the 2010 ASCO annual meeting in Chicago.
The original article, A randomized study with adjuvant mistletoe versus oral Etoposide on post relapse disease-free survival in osteosarcoma patients,
was published in 2009 in the European Journal of Integrative Medicine. You will find the abstract below and you can request a pdf-file of the entire study from email@example.com
Background: Osteosarcoma is a highly malignant bone tumor affecting mainly adolescents. While it can be cured in approximately 60% of cases with the recommended neoadjuvant chemotherapy, few experimental target drugs are currently available through phases I and II trials for relapsed and inoperable patients. We know from historical controls that the risk to relapse increases after the second relapse. Relapse-free survival then decreases to o20% at 12 months. Oral Etoposide is often used in clinical practice but outside any protocol or evidence of improved survival.
Methods and Materials: Viscum album fermentatum Pini (Viscum) is a highly popular phytocompound across central Europe with immuno-modulatory activity. Encouraged by the preliminary findings of a pilot study that showed a prolonged disease-free survival (DFS) of more than 12 months in four of our five osteosarcoma patients after their second relapse, we started a two-arm randomized study comparing Viscum album fermentatum Pini s.c. to oral Etoposide for patients free from disease after their second metastatic relapse. Our aim is to compare the disease-free survival to a historical group of patients at 12 months.
Results: To date, the median follow-up is 9.5 months while the study is in progress. The median DFS is currently 3 months for Etoposide and 8.5 months for Viscum. Patients on Viscum report a higher quality of life due to lower toxicity, compared to Etoposide.
Conclusion: In-depth study of the immunomodulatory mechanisms of Viscum in osteosarcoma patients is required. Viscum shows promise as adjuvant treatment in prolonging DFS after a second relapse, while Etoposide does not seem to prolong the DFS in patients after their second relapse. A larger multi-center trial is required to determine efficacy of therapy in osteosarcoma patients. Preliminary data are reported.